Myasthenia Gravis Treatment Market Will Experience Growth, Reaching US$4.1 Billion by the End of 2030, Predicts Persistence Market Research
January 23, 2024 01:45 ET
|
Persistence Market Research
New York, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Myasthenia Gravis Treatment Market Poised for Steady Growth, driven by Innovation and Rising Awareness The global market for myasthenia gravis (MG)...
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
January 22, 2024 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
– Preliminary Data from ATH434-202 Study Expected in 1H 2024 –– ATH434-201 Study to Complete in November 2024 – MELBOURNE, Australia and SAN FRANCISCO, Jan. 22, 2024 (GLOBE NEWSWIRE) --...
Contract Research Organization Market revenue to hit USD 108 Billion by 2035, says Research Nester
January 15, 2024 06:00 ET
|
Research Nester
New York , Jan. 15, 2024 (GLOBE NEWSWIRE) -- The global contract research organization market size is slated to expand at 7% CAGR between 2023 and 2035. The market is poised to garner a revenue of...
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority
January 03, 2024 09:46 ET
|
Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Huntington’s disease (HD) could be called the perfect storm of neurodegenerative diseases. It causes a loss of critical striatal neurons which affect not...
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
December 21, 2023 00:30 ET
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
December 18, 2023 06:30 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
December 15, 2023 09:05 ET
|
Biogen Inc.
Friedreich’s ataxia is a genetic, debilitating and life-shortening neuromuscular disease1Milestone highlights Biogen’s growing portfolio in rare diseases and focus on addressing unmet needs of...
U.S. Neurologists Eagerly Await Promising Oral Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement
December 13, 2023 14:03 ET
|
Spherix Global Insights
Exton, PA, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Several clinical trials are underway for Bruton’s tyrosine kinase inhibitors (BTKi) targeting relapsing and progressive multiple sclerosis (RMS/PPMS)....
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
December 12, 2023 07:00 ET
|
Athira Pharma, Inc.
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative...
Global Medical Imaging Market Size to Reach USD 52.03 Billion in 2032 | Emergen Research
December 07, 2023 09:10 ET
|
Emergen Research
Vancouver, Dec. 07, 2023 (GLOBE NEWSWIRE) -- The global medical imaging market, valued at USD 52.03 Billion in 2032, is set to experience substantial growth, with a projected revenue Compound Annual...